PAION AG: Court sanctions Scheme of Arrangement for acquisition of CeNeS(06/24/2008) The management board of PAION AG and the board of directors of CeNeS Pharmaceuticals plc announced that at the Court Hearing, the Court of Session in Edinburgh, Scotland, sanctioned the Scheme of Arrangement, which describes the terms and conditions ...
PAION sees continued development rationale for Desmoteplase based on findings from Phase III analysis(10/22/2007) Reasons identified for high placebo response rate in Phase III stroke study DIAS-2 PAION AG reported that it has reviewed findings from the analysis of the DIAS-2 (Desmoteplase in Acute ischemic Stroke) study results. In contrast to previous Phase II studies, the DIAS-2 study did not meet its primary efficacy endpoint due to a ...
PAION reduces number of employees(06/27/2007) PAION AG announced that the management board and the supervisory board agreed on an action plan to significantly reduce external and internal costs. The decision was taken based on the unexpected results of the Phase III study DIAS-2 which was ...
Paion initiates programme of next generation plasminogen activators(03/28/2006) PAION AG announced the initiation of a new plasminogen activator programme, which is intended to serve as a long-term life cycle management tool for Desmoteplase and a mid term option for indications not within the current profile and development ...
Top
